Journal of Liver Cancer

Original Article

Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma: Jun Seok, Ki Tae Suk; J Liver Cancer. 2020;20(1):32-40. Published online March 31, 2020; DOI: https://doi.org/10.17998/jlc.20.1.32

9,723 Views
261 Downloads
8 Citations

Background/Aims
Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer and the fifth leading cause of worldwide cancer mortality. Though early diagnosis of HCC is important, so far lack of effective biomarkers for early diagnosis of HCC has been a problem. In this study, we searched for potential functional biomarkers of alcoholic HCC by using metagenomics approach.
Methods
Between September 2017 and April 2019, normal control (n=44), alcoholic liver cirrhosis (n=44), and alcoholic HCC (n=13) groups were prospectively enrolled and analyzed. Gut microbiota was analyzed using the 16S-based microbiome taxonomic profiling platform of EzBioCloud Apps and analyzing system.
Results
There was a statistically significant difference among groups in diversity (P<0.05). In the comparison of phylum between cirrhosis and HCC, Proteobacteria were increased and Bacteroidetes were decreased. Firmicutes were not significantly different among the three groups. In the taxonomic profiling, relative abundance of Lactobacillus in the cirrhosis and HCC groups showed richness (P<0.05). In the biomarker analysis between cirrhosis and HCC, obiquinome Fe-S protein 3, global nitrogen regulator, Vesicle-associated membrane protein 7, toxin YoeB, peroxisome-assembly ATPase, and nitrogen oxide reductase regulator were differently expressed (P<0.001).
Conclusions
Alcoholic HCC showed different expressions in the stool taxonomy and biomarker compared with that of cirrhosis and control. Therefore, new biomarkers using stool analysis for alcoholic HCC are necessary.

Citations

Citations to this article as recorded by

Composition of gut microbiota and alcohol-related liver disease: A systematic review and meta-analysis
Xuanxuan Niu, Lei Ma, Zhewen Zhou, Yan Li, Anyi Shi, Lihan Weng, Huichun Xing
Drug and Alcohol Dependence.2026; 278: 112988. CrossRef
Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities
Huiping Zhou, Yi Huang, Chen Chen, Meiyi Song, Phillip B. Hylemon
Pharmacological Reviews.2026; 78(2): 100120. CrossRef
Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential
Xulan Zhang, Yi Xia, Feng Ji
Probiotics and Antimicrobial Proteins.2026;[Epub] CrossRef
A Systematic Review of Microbiota in Cirrhosis: A Change Towards a More Pathogenic Predisposition
Elias Xirouchakis, Alexandros Pelekanos, Spyridon Xirouchakis, Hariklia Kranidioti, Spilios Manolakopoulos
International Journal of Molecular Sciences.2025; 26(2): 527. CrossRef
Distinct Gut Microbiota Profiles Associated with Advanced Hepatocellular Carcinoma in a Thai Cohort: A 16S rRNA Sequencing Study
Thanakorn Charoenthanadhol, Jutarop Phetcharaburanin, Theerayut Bubpamala, Aumkhae Sookprasert, Jarin Chindaprasirt, Thanachai Sanlung, Piyakarn Watcharenwong, Siraphong Putraveephong, Kosin Wirasorn
Cancers.2025; 17(17): 2915. CrossRef
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study
Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim
Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991. CrossRef
Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression
Lin Cui, Xiaohui Xu, Hui Fan, Xinyan Wan, Qian Chen, Junhui Zhang, Chuntao Tao, Zheng Du, Yitao Wang, Jian Zhang, Jun Zeng, Ying Zhang, Chundong Zhang, Longhao Li, Youquan Bu, Yunlong Lei
Cancer Letters.2024; 601: 217183. CrossRef
Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development
Nevena Todorovic, Serena Martinelli, Giulia Nannini, Ralf Weiskirchen, Amedeo Amedei
International Journal of Molecular Sciences.2024; 25(24): 13510. CrossRef

Case Report

A Case of Surgical Resection in Hepatocellular Carcinoma with Pulmonary Metastasis: Woo Jin Jung, Jae Young Jang, Jun Seok Park, Hee Jeong Lee, Young Kyu Cho, Soung Won Jeong, Sae Hwan Lee, Snag Gyune Kim, Sang Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim; J Liver Cancer. 2016;16(2):145-150. Published online September 30, 2016; DOI: https://doi.org/10.17998/jlc.16.2.145

2,409 Views
14 Downloads

Abstract PDF: Hepatocellular carcinoma (HCC) is well known malignancy with poor prognosis, even after resection of the primary tumor. Sorafenib is the first-line treatment in advanced HCC, but the disease control rate of sorafenib is only 43%. Pulmonary metastasectomy in patients with pulmonary metastasis from HCC has been reported to increase long-term survival compared with systemic chemotherapy. Video-assisted thoracic surgery is considered a reliable approach to the diagnosis and treatment of pulmonary diseases with low complication rate. Pulmonary metastasectomy is not universally accepted because of frequent local recurrence, an uncontrollable primary tumor, and frequent multiple pulmonary metastases in HCC, but outcome of pulmonary metastasectomy and adjuvant sorafenib therapy has not been studied. We experienced a patient who had advanced HCC with pulmonary oligometastasis and received surgical resection of the metastatic pulmonary nodule and sorafenib chemotherapy. In advanced HCC with pulmonary oligometastasis, surgical resection of pulmonary metastasis and sorafenib chemotherapy should be considered.

First
Prev
Page of 1
Next
Last

Search